The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Recent U.S. domestic news covers the FDA investigating deaths post-gene therapy by Sarepta, discussions at a CDC advisory ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Novo Nordisk NVO ended its collaboration agreement with telehealth company Hims & Hers Health HIMS to offer its blockbuster ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...